Been watching Eli Lilly's run and there's something that's been bothering me about the narrative everyone's pushing right now.

Don't get me wrong - the GLP-1 story is real. Mounjaro's up 99% in sales, Zepbound jumped 175%. These are genuinely impressive numbers and Eli Lilly absolutely nailed the execution here. Their formulations are legitimately better than what competitors brought to market first. But here's where I'm skeptical: everyone already knows this. The market's priced it in completely.

Look at the valuation. We're talking a P/E of 44 when the S&P 500 average sits around 28 and pharma stocks typically trade at 23. That's not just premium pricing - that's betting the entire future on GLP-1 dominance continuing forever. And here's the thing that worries me: Eli Lilly's got 56% of its revenue and basically all its growth coming from these two drugs. That's concentration risk most investors aren't really grappling with.

The pharmaceutical industry has this pattern, right? Someone dominates, then they don't. Novo Nordisk got there first but Eli Lilly had the better product. Now Pfizer and others are moving into the space. In a decade, will Eli Lilly still be the king? Maybe, maybe not. Patent cliffs are real too - these drugs won't have protection forever. Generic competition could hit hard and fast once patents expire.

I get that management is building the pipeline for tomorrow. But if you're buying at these valuations, you're essentially betting that Eli Lilly stays on top and that the GLP-1 cash flows keep flowing at these levels. That's a lot of faith to put in one company, one drug class, in an industry that's historically humbled even the biggest players. Worth thinking about before loading up.